What happened at our partners… September 2023 edition
In September, ITQB NOVA celebrated its first Postdoc Appreciation Week, an international event that recognizes the contributions of postdocs to research, discovery, and outreach efforts. The entire ITQB NOVA community came together to express their gratitude for postdocs, sharing their appreciation through photos and letters. Throughout the week, ITQB NOVA and iBET postdocs participated in a wide range of sessions and workshops, from social media to narrative CVs.
See more here.
For the first time, NOVA Medical School (NMS) organized the Estoril Conferences in partnership with NOVA School of Business and Economics, an event that brought together some of the world’s foremost experts on September 1st and 2nd to discuss cross-cutting topics for the future. Under the theme “Re-humanizing the future,” the 2023 edition of these conferences once again served as a forum for dialogue, sharing, and reflection in key areas such as the Planet, People, Health, Peace, and global Policy. It was an intense event with a full house, attended by leaders, academics, entrepreneurs, artists, and youth.
Find out more here.
iBET researchers presented ongoing work at the at the 1st International Conference of the Portuguese Association of Cellular Agriculture and discussed how we can use bioprocesses knowledge to such a growing industry.
See more here.
Three groundbreaking projects from Portugal have been chosen as awardees of the ERC Starting Grant scheme in Life Sciences, securing a total funding of over €5M. Of these, two distinguished recipients are Ilana Gabanyi and Giulia Ghedini from the Gulbenkian Science Institute.
Read more here.
A recent paper on “Metabolites” is an excellent example of the collaborative effort between our partner Institutes and the translational research work developed by our different labs. Check here the latest publication coordinated by LS4FUTURE members from IPO Lisboa, NMS and ITQB NOVA, titled “Peripheral blood serum NMR metabolomics is a powerful tool to discriminate benign and malignant ovarian tumors“.